| pubmed-article:18392862 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18392862 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18392862 | lifeskim:mentions | umls-concept:C0034380 | lld:lifeskim |
| pubmed-article:18392862 | lifeskim:mentions | umls-concept:C0521324 | lld:lifeskim |
| pubmed-article:18392862 | lifeskim:mentions | umls-concept:C0205245 | lld:lifeskim |
| pubmed-article:18392862 | lifeskim:mentions | umls-concept:C0009566 | lld:lifeskim |
| pubmed-article:18392862 | lifeskim:mentions | umls-concept:C0085862 | lld:lifeskim |
| pubmed-article:18392862 | lifeskim:mentions | umls-concept:C0425245 | lld:lifeskim |
| pubmed-article:18392862 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:18392862 | pubmed:dateCreated | 2008-7-28 | lld:pubmed |
| pubmed-article:18392862 | pubmed:abstractText | INTRODUCTION: Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life. DISCUSSION: Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein. | lld:pubmed |
| pubmed-article:18392862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18392862 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18392862 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18392862 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18392862 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18392862 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18392862 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18392862 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18392862 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18392862 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18392862 | pubmed:issn | 0941-4355 | lld:pubmed |
| pubmed-article:18392862 | pubmed:author | pubmed-author:CostaLuisL | lld:pubmed |
| pubmed-article:18392862 | pubmed:author | pubmed-author:LiptonAllanA | lld:pubmed |
| pubmed-article:18392862 | pubmed:author | pubmed-author:ChowEdwardE | lld:pubmed |
| pubmed-article:18392862 | pubmed:author | pubmed-author:BadiaXavierX | lld:pubmed |
| pubmed-article:18392862 | pubmed:author | pubmed-author:WardleyAndrew... | lld:pubmed |
| pubmed-article:18392862 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18392862 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:18392862 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18392862 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18392862 | pubmed:pagination | 879-89 | lld:pubmed |
| pubmed-article:18392862 | pubmed:dateRevised | 2009-1-2 | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:meshHeading | pubmed-meshheading:18392862... | lld:pubmed |
| pubmed-article:18392862 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18392862 | pubmed:articleTitle | Impact of skeletal complications on patients' quality of life, mobility, and functional independence. | lld:pubmed |
| pubmed-article:18392862 | pubmed:affiliation | Instituto de Medicina Molecular-Lisboa, Servico de Oncologia, Hospital de Santa Maria, Av Professor Egaz Moniz, Lisbon, 1649-039, Portugal. luiscosta.p@netcabo.pt | lld:pubmed |
| pubmed-article:18392862 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18392862 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:18392862 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18392862 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18392862 | lld:pubmed |
